8 months ago
SANA
AnalystsEmily BodnarEmily Bodnar's Stock Forecasts
AnalystsEmily Bodnar
Sectors:
Analyst Ranking
Bottom 1%
#5013 out of 5017 analysts
Average Return
-17.8%
Win Rate
27%82 out of 299
Risk vs Reward
Poor
Good
Emily Bodnar's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Gracell Biotechnologies IncGRCL | +372.38% | $2.10 | $9.92 | 2023-02-15 - 2023-12-26 | Buy |
Gracell Biotechnologies IncGRCL | +322.13% | $2.35 | $9.92 | 2023-02-05 - 2023-12-26 | Buy |
Mink Therapeutics IncINKT | +313.74% | $6.77 | $28.01 | 2024-10-08 - 2025-07-15 | Buy |
Mink Therapeutics IncINKT | +271.49% | $7.54 | $28.01 | 2024-11-14 - 2025-07-15 | Buy |
Gracell Biotechnologies IncGRCL | +254.29% | $2.80 | $9.92 | 2023-05-25 - 2023-12-26 | Buy |
Emily Bodnar Analyst Color
Get additional color on Emily Bodnar's coverage of popular stocks
2 years ago
FEMY
Emily Bodnar's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Agenus IncAGEN | 14 | Buy | $23.00 | +416.85% | Reiterates | 7 days ago |
Agios Pharmaceuticals IncAGIO | 2 | Buy | $56.00 | +54.27% | Reiterates | 12 days ago |
Briacell Therapeutics CorpBCTX | 15 | Buy | $40.00 | +394.44% | Maintains | 21 days ago |
Mink Therapeutics IncINKT | 14 | Buy | $35.00 | +145.27% | Upgrades | a month ago |
Vtv Therapeutics IncVTVT | 2 | Buy | $36.00 | +76.38% | Reiterates | a month ago |
Femasys IncFEMY | 25 | Buy | $8.00 | +2,079.84% | Maintains | a month ago |
Context Therapeutics IncCNTX | 10 | Buy | $4.00 | +392.61% | Maintains | a month ago |
Sab Biotherapeutics IncSABS | 2 | Buy | $9.00 | +328.57% | Maintains | 2 months ago |
Rapt Therapeutics IncRAPT | 2 | Buy | $27.00 | +55.04% | Maintains | 2 months ago |
Jasper Therapeutics IncJSPR | 10 | Buy | $20.00 | +740.34% | Maintains | 2 months ago |
Nextcure IncNXTC | 9 | Buy | $36.00 | +554.55% | Reiterates | 3 months ago |
Arcellx IncACLX | 13 | Buy | $115.00 | +52.93% | Reiterates | 3 months ago |
Artiva Biotherapeutics IncARTV | 1 | Buy | $12.00 | +410.64% | Assumes | 3 months ago |
Anaptysbio IncANAB | 9 | Buy | $38.00 | +88.49% | Upgrades | 3 months ago |
Olema Pharmaceuticals IncOLMA | 19 | Buy | $30.00 | +275.00% | Reiterates | 5 months ago |
Sana Biotechnology IncSANA | 10 | Buy | $11.00 | +240.56% | Reiterates | 5 months ago |
Transcode Therapeutics IncRNAZ | 17 | Buy | $280.00 | +2,457.08% | Maintains | 5 months ago |
Connect Biopharma Holdings LtdCNTB | 6 | Buy | $8.00 | +400.00% | Reiterates | 5 months ago |
Io Biotech IncIOBT | 13 | Buy | $12.00 | +552.17% | Reiterates | 6 months ago |
Genelux CorpGNLX | 7 | Buy | $30.00 | +665.31% | Reiterates | 6 months ago |
Acrivon Therapeutics IncACRV | 11 | Buy | $19.00 | +1,158.28% | Reiterates | 6 months ago |
Nkarta IncNKTX | 13 | Buy | $18.00 | +813.71% | Reiterates | 6 months ago |
Imunon IncIMNN | 13 | Buy | $210.00 | +3,663.44% | Reiterates | 6 months ago |
Atossa Therapeutics IncATOS | 13 | Buy | $7.00 | +755.75% | Reiterates | 6 months ago |
Arcus Biosciences IncRCUS | 5 | Buy | $24.00 | +107.25% | Upgrades | 7 months ago |
Tenaya Therapeutics IncTNYA | 1 | Buy | $18.00 | +1,400.00% | Reiterates | 7 months ago |
Novocure LtdNVCR | 18 | Buy | $38.00 | +198.74% | Reiterates | 8 months ago |
Acelyrin IncSLRN | 13 | Hold | $6.00 | +164.32% | Maintains | 8 months ago |
Geron CorpGERN | 3 | Buy | $9.00 | +608.66% | Reiterates | 9 months ago |
Purple Biotech LtdPPBT | 13 | Buy | $33.00 | +5,740.71% | Reiterates | 10 months ago |
Ventyx Biosciences IncVTYX | 13 | Hold | $6.00 | +160.87% | Reiterates | 10 months ago |
Gracell Biotechnologies IncGRCL | 6 | Hold | $10.00 | N/A | Downgrades | 2 years ago |
Dice Therapeutics IncDICE | 8 | Hold | $48.00 | N/A | Reiterates | 2 years ago |
Sqz Biotechnologies CoSQZB | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.